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Functional status and long term outcome of stroke
Despite undoubted progress, we still have much to do
Despite advances in prevention, acute care, and reha-
bilitation the prognosis after acute stroke remains poor: 
20-30% of patients die within a month and 13% of 
survivors are discharged to institutional care.1 2 In the 
accompanying prospective cohort study, Bruin Slot and 
colleagues report that functional status at six months 
after stroke is associated with long term survival.3 The 
median survival of patients who were independent at 
this stage was 9.7 years compared with 6.0 years for 
those who were dependent. The effect of functional 
outcome at six months on mortality was independent 
of age and stroke subtype. The study gives no details 
about the causes of death or whether secondary pre-
vention was optimised, but these survival data again 
emphasise the impact of stroke. They also suggest that 
early treatment known to reduce dependency at six 
months may have a substantial longer term effect.
Stroke care and the evidence base on which serv-
ices are developed have improved considerably since 
1981, when one of the cohorts described in the study 
(the Oxfordshire community stroke project) was estab-
lished.4 In the past, people with stroke were too often 
discharged without consideration for their ongoing 
needs and carer support.
Most acute trusts in the United Kingdom now have 
a stroke unit and in the United States the Brain Attack 
Coalition recommended similar primary stroke centres 
in 2000; at that time only 7% of hospitals surveyed met 
all recommended elements, although 44% provided 
most services. Furthermore, many shortcomings still 
need to be resolved. The UK 2006 national sentinel 
stroke audit found that although all eligible patients 
with ischaemic stroke received antiplatelet drugs, only 
70% received blood pressure lowering drugs, only 78% 
received cholesterol lowering drugs, and only 34% of 
patients in atrial fibrillation were anticoagulated at dis-
charge. Thus, secondary prevention could be improved 
and mortality and morbidity after stroke could be 
reduced if these highly effective treatments were more 
widely implemented.2 These problems in implementa-
tion of the evidence base are not unique to the UK. 
Stroke units improve independence and survival at 
six months, but in 2006 only 62% of patients in the 
UK were admitted to a stroke unit and only 54% spent 
more than half of their inpatient stay on one.2 Throm-
bolysis given within the first three hours of ischaemic 
stroke reduces death and disability at three to six 
months,5 yet only 30 trusts in the UK provide this 
service, and even fewer provide it at all hours of the 
day.2 Up to 20% of stroke patients may be eligible for 
thrombolytic treatment, yet in 2006 only 218 patients—
less than 0.5% of patients with acute ischaemic stroke 
in England, Wales, and Northern Ireland—received 
thrombolysis.2 In a large study in the US the equivalent 
rate was 1.12%. Early supported discharge by a special-
ist stroke team can also improve outcome, yet provi-
sion of this service is limited.6 All of this emphasises 
the problem of translating research into practice, which 
was highlighted by the recent Cooksey report.7
Service development and research have focused 
on prevention and care soon after stroke. Relatively 
few studies, however, have looked at interventions 
for improving longer term outcomes for survivors of 
stroke and their carers.8 Service provision focusing on 
long term needs is also sparse. Patients with stroke 
and their carers often report feeling abandoned after 
discharge and that they are badly informed and sup-
ported, both practically and emotionally.1 9
Even less is known about how to minimise the long 
term effects of stroke. The 2001 national service frame-
work for older people suggested that patients with 
stroke and severe disability should be reviewed at six 
months.10 One of the purposes of the review would 
be to deal with patients’ and carers’ concerns. Bruin 
Slot and colleagues suggest that prognostic information 
could be given to patients and their relatives at six 
months.3 Arguably, before providing more information 
about risks and prognosis at six months, much could be 
done to improve communication soon after a stroke. 
The information needs and priorities of patients and 
their carers change over time, and it is important for 
the right information to be provided in the right way, 
at the right time, and in the right format.11 12
It is increasingly acknowledged that patients and 
carers should be active participants in decisions about 
the care they receive. Enabling patients and carers to 
have meaningful input into service development and 
to be actively involved with clinicians about deciding 
treatment options will result in care that is responsive 
to their needs and likely to lead to better outcomes.
The national stroke strategy, published by the UK 
Department of Health in early December 2007, once 
again emphasises the importance of implementing 
evidence based practice as well as involving patients, 
carers, health professionals, social services, and chari-
ties in shaping local stroke services.1 Let us hope that 
these admirable aims will become the template for both 
commissioners and providers of care to seize the oppor-
tunity to enhance the health and wellbeing of a substan-
tial and, to date, underserved group of patients.
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Self management training in refractory angina
may improve health related quality of life and cut treatment costs
Refractory angina pectoris is a major clinical problem 
characterised by unremitting symptoms of angina (equiv-
alent to severity score class III-IV on the Canadian Car-
diovascular Society classification), which are resistant to 
conventional treatments including nitrates, calcium chan-
nel and β adrenoceptor blockade, percutaneous coro-
nary interventions, and coronary artery bypass grafting.1 
Although there are limitations in current surveillance sys-
tems worldwide, estimates from data on revascularisation 
and hospital admission suggest a prevalence of refractory 
angina somewhere between 600 000 and 1.8 million in 
the United States and an incidence of 30-50 000/year in 
continental Europe.1 2
Patients with refractory angina experience persistent 
anginal pain, poor general health status, psychological 
distress, restriction of activity, and inability to self manage 
their symptoms—all of which have a negative effect on 
health related quality of life.1 2
Self management training that includes cognitive 
behaviour techniques is showing promise in angina.3 4 
Indeed, it could be a welcome standard addition to the 
current technically based effective interventions aimed 
solely at reducing ischaemia.1 2
Among the most feasible, well established, and widely 
used therapeutic options at present are neuromodulation 
techniques such as transcutaneous electrical nerve stimu-
lation and spinal cord stimulation.1 2 These techniques 
can relieve anginal pain secondary to reducing ischae-
mia. Their anti-ischaemic effect is probably a product of 
decreased myocardial oxygen consumption,1 although 
amelioration of coronary blood flow and neurohormonal 
mechanisms may also contribute.5 Spinal cord stimula-
tion can also significantly improve health related quality 
of life.6 Invasive analgesic strategies, such as stellate gan-
glion blockade and thoracic epidural analgesia, are also 
an important part of the current armamentarium.1 2 7
These treatments are expensive, however, and they 
require specialist angina centres with the requisite surgi-
cal and technical expertise. For example, one technique—
enhanced external counterpulsation—involves application 
of a series of pneumatic cuffs that sequentially compress 
the calves and thighs.8 It reduces anginal symptoms and 
the need to use nitrates, and it improves time to exercise 
induced ischaemia, but a typical treatment regimen com-
prises more than 30 treatment sessions of one hour over 
the course of several weeks.8
Self management training is a promising adjunct to 
the treatment of refractory angina that needs relatively 
few resources, but few studies have been carried out in 
this patient population. Self management training inter-
ventions are multimodal treatment packages that use 
learning materials and cognitive behaviour strategies to 
promote effective self management of disease. In the past 
decade, a few small self management trials have shown 
significant reductions in the frequency of angina symp-
toms, use of nitrates, stress, and aspects of self reported 
health related quality of life.3 While these findings are 
promising, they come from trials in single sites that have 
short term follow-up (three to six months); methodologi-
cal problems such as small sample sizes, lack of standard-
ised and replicable interventions, and heterogeneity of 
measures. These trials have also included patients with 
less severe Canadian Cardiovascular Society class I-II 
symptoms. All of these factors limit the interpretation 
and generalisability of the findings.3
A more recent and robust trial with 142 participants 
showed that a self management programme based on 
cognitive behaviour therapy significantly reduced anxi-
ety, depression, frequency of symptoms, nitrate use, and 
physical limitations (P<0.05) at six months compared 
with usual care.4 This model was designed and tested 
for patients with newly diagnosed angina, and this 
research should be adapted and tested for patients with 
refractory angina.
Investing time and money in robust trials of self man-
agement in refractory angina could be worthwhile. Rig-
orous trials of patients with other complex diseases have 
accrued overwhelming evidence for the feasibility, long 
term effectiveness, cost effectiveness, and widespread 
dissemination of self management interventions led 
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by healthcare professionals and peers.9-12 For example, 
self management training significantly improves health 
related quality of life in patients with complex chronic 
pain,9 arthritis,10 and other chronic illnesses.11 Significant 
reductions in rates of admission to hospital, length of 
hospital stay, mean number of visits to doctors, and direct 
out of pocket costs to patients have also been consistently 
reported.10 11
Mannheimer C, Camici P, Chester MR, Collins A, DeJongste M, Eliasson 1 
T, et al. The problem of chronic refractory angina; report from the ESC 
Joint Study Group on the Treatment of Refractory Angina. Eur Heart J 
2002;23:355-70.
Bhatt AB, Stone PH. Current strategies for the prevention of angina 2 
in patients with stable coronary artery disease. Curr Opin Cardiol 
2006;21:492-502.
McGillion M, Watt-Watson J, Kim J, Yamada J. A systematic review of 3 
psychoeducational intervention trials for the management of chronic 
stable angina. J Nurs Manag 2004;12:174-82.
Lewin RJP, Furze G, Robinson J, Griffith K, Wiseman S, Pye M, et al. A 4 
randomized controlled trial of a self-management plan for patients 
with newly diagnosed angina. Br J Gen Pract 2002;52:194-6.
Eliasson T, Mannheimer C, Waagstein F, Andersson B, Bergh CH, 5 
Augustinsson LE, et al. Myocardial turnover of endogenous opioids 
and calcitonin-gene-related peptide in the human heart and the 
effects of spinal cord stimulation on pacing-induced angina pectoris. 
Cardiology 1998;89:170-7.
Ekre O, Eliasson T, Norrsell H, Wahrborg P, Mannheimer C. Long-6 
term effects of spinal cord stimulation and coronary artery bypass 
grafting on quality of life and survival in the ESBY study. Eur Heart J 
2002;23:1938-45.
Chester M, Hammond C, Leach A. Long-term benefits of stellate 7 
ganglion block in severe chronic refractory angina. Pain 
2000;87:103-5.
Arora RR, Chou TM, Jain D, Fleishman B, Crawford L, McKiernan T, et al. 8 
The multicenter study of enhanced external counterpulsation (MUST-
EECP): effect of EECP on exercise-induced myocardial ischemia and 
anginal episodes. J Am Coll Cardiol 1999;33:1833.
LeFort S, Gray-Donald K, Rowat KM, Jeans ME. Randomised controlled 9 
trial of a community based psychoeducation program for the self-
management of chronic pain. Pain 1998;74:297-306.
Lorig K, Mazonson P, Holman HR. Evidence suggesting that health 10 
education for self-management in patients with chronic arthritis has 
maintained health benefits while reducing health care costs. Arthritis 
Rheum 1993;36:439-46.
Lorig KR, Sobel DS, Stewart AL, Brown BW, Ritter PL, Gonzalez VM, 11 
et al. Evidence suggesting that a chronic disease self-management 
program can improve health status while reducing utilization and 
costs: a randomized trial. Med Care 1999;37:5-14.
Lorig KR, Margo-Lea H, Sobel D, Hobbs M, Ritter L. A national 12 
dissemination of an evidence-based self-management program: a 
process evaluation study. Patient Educ Couns 2005;59:69-79.
Interpreting trends in fecundity over time
is complicated by the lack of direct markers
Jens Peter Ellekilde Bonde 
professor of occupational 
medicine, Department of 
occupational medicine, aarhus 
University Hospital, DK-8000 
aarhus, Denmark 
jpbon@as.aaa.dk
Jørn Olsen professor of 
epidemiology, Department of 
Epidemiology, University of 
california, 90095-1772 los 
angeles, Usa
Competing interests: none 
declared.
Provenance and peer review: not 
commissioned; not externally peer 
reviewed.
BMJ 2008;336:339-40
doi: 10.1136/bmj.39463.522708.80
Infertility is a common problem in affluent societies. 
It affects around 15% of couples trying to conceive, 
although not all seek medical help.1 In some countries, 
up to 6% of children are conceived through assisted 
reproductive techniques.2 Many young men have sperm 
counts that fall short of the limit known to be associ-
ated with reduced fecundity.3 It is still unclear whether 
the past decades have seen a substantial change in the 
fertility of couples in general or in the fertility of men 
in particular.4
The few studies that have examined changes in fecun-
dity over time (or menstrual cycles)—from discontinu-
ation of contraception to pregnancy—show conflicting 
results.5 Fertility in couples is determined by social, 
behavioural, and biological factors that cannot be reli-
ably ascertained in studies based on retrospectively col-
lected data. Therefore, we will never know if biological 
fertility has changed.5 Findings of numerous studies of 
secular trends in sperm counts are far from conclu-
sive, but a study by Jensen’s group provides convincing 
evidence of a pronounced difference in semen quality 
between populations.6 Moreover, another recent paper 
from the same group shows that in cohorts of Dan-
ish women born between 1960 and 1980, birth rates 
decline progressively after adjustment for children con-
ceived by assisted reproduction. The results are even 
more pronounced when the sharply declining rate of 
induced abortions is accounted for.7
However, biological fecundity is just one of the 
many determinants of fertility. These include sexual 
behaviour, desire for a given family size, social condi-
tions, the age at which people start to have children, 
use of family planning methods, and the availability of 
assisted reproductive techniques. These cultural and 
social norms may mask more subtle biological changes 
in the population. More direct markers of fecundity 
are urgently needed, and the time has probably come 
to include fecundity in ongoing representative health 
surveys. Drawing on the present understanding of the 
methodological pitfalls in fertility research, we may be 
able to collect prospective data that are sufficiently com-
parable over time. Such studies may detect changes in 
fecundity similar in size to those reported in the past.
In any case fecundity is expected to decline over 
time, even if no evident causative environmental expo-
sures are present.8 This is because fecundity probably 
has a strong genetic component. With the advent of 
assisted conception, subfertile couples may have as 
many children as fertile couples, so that genetic factors 
linked to infertility will become more prevalent in the 
generations to come.9
From a public health perspective research should 
focus on avoidable causes of subfecundity. Such studies 
should look at exposure from the time of development 
of the sexual organs in the fetus to the time of trying to 
become pregnant. The first time point may be at least 
as important as the second. Thus, promising new results 
show that intrauterine exposure deserves close atten-
tion, and that both lifestyle and environmental factors 
should be the focus of further studies.10 11 One study 
found a threefold higher prevalence of DNA damage 
in infertile men with Chlamydia trachomatis infection of 
the genitourinary tract than in fertile men without infec-
tion.12 Treatment with antibiotics reduced the signs of 
DNA damage, and the female partners of a small subset 
of patients became pregnant after the treatment ended. 
The cross sectional design of the study means the find-
ings should be interpreted with caution, and further 
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The report of the committee of enquiry into Ely Hos-
pital, Cardiff, in 1969, was the first major inquiry into 
quality failures in the National Health Service. Thirty 
years later the report of the expert group chaired by 
the chief medical officer, An Organisation with a Memory, 
emphasised the need for the NHS to learn from its mis-
takes, and to be more systematic in acting on inquiry 
reports. A new analysis by the Healthcare Commission 
builds on these reports by summarising lessons from 
13 major investigations it has undertaken since 2004.
Readers of the commission’s report can be forgiven if 
they experience a strong sense of déjà vu. Although the 
investigations it undertook covered a wide range of serv-
ices in different parts of the country, the general themes 
that emerge are depressingly familiar. The quality fail-
ures examined resulted from the interplay of several 
factors, including weak leadership, conflicting targets, 
inadequate use of data, and lack of teamwork. One of 
the problems highlighted in the commission’s report 
is the poor standard of care found on general hospital 
wards, including examples of patients not being helped 
to eat their food and not being given their drugs.
Why is it so difficult to learn from mistakes and 
reduce avoidable errors? Part of the answer lies in the 
sheer size of the NHS and the large number of interac-
tions between patients and providers that occur each 
day. In the absence of well developed systems to pro-
mote consistently high standards of care, mistakes are 
likely to occur, sometimes with tragic consequences.
In fact, the problems investigated by the commis-
sion were less the result of individual failings than the 
consequence of institutional shortcomings. The story 
that emerges from its report is of hospitals and serv-
ices lacking effective direction and tolerating ways of 
working in which quality failures are accepted rather 
than challenged. In the words of the chief medical 
officer’s report, the institutions concerned lacked a 
“safety culture” and were therefore at risk of patients 
being abused and adverse events occurring.
What needs to be done to restore memory to NHS 
organisations? A major step forward would be for min-
isters and civil servants to heed the warnings contained 
in the report about the negative consequences of con-
tinuous organisational restructuring on the quality of 
patient care. As the report states, “if not carefully man-
aged, the process of organisational change can divert 
management away from maintaining service quality.”
Equally important is the need to ensure that NHS 
boards pay as much attention to quality and safety as 
financial balance and hitting government targets. In 
theory, the duty of clinical governance laid on the NHS 
in 1999 should have persuaded chief executives to take 
quality seriously. The evidence reported here shows that 
this has not happened universally, nor have board mem-
bers always used and questioned the data presented to 
them to exercise their stewardship role effectively.
Even more challenging will be bringing about the 
changes in culture that will enable the NHS to achieve 
the same level of safety as the airline and nuclear power 
industries. Among other things, this entails putting in 
place systems designed to reduce errors, providing 
appropriate training and development for staff, and 
ensuring that mistakes are measured and monitored. 
Above all, NHS organisations need to encourage the 
open reporting of adverse events and avoid staff feeling 
they will be blamed when things go wrong.
studies are needed to confirm the results.
The best way to counteract infertility and help couples 
to have children naturally is to deal with the avoidable 
causes of subfecundity. Disappointingly, a large new 
programme for establishing research centres in repro-
duction and infertility in the United States devoted little 
attention to the environmental causes of subfecundity. 
There are good grounds for promoting further research 
and for trying to make up for the many years during 
which research into infertility has been neglected. The 
endocrine disruption hypothesis—which states that 
environmental chemicals may cause adverse develop-
ment of sexual organs by interference with hormonal 
regulation—is just one of many hypotheses that deserve 
attention from funding agencies.11
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How can Europe produce medical research that will 
best increase its citizens’ health and its countries’ 
wealth? This debate will run on and on, of course, 
but a new white paper from the European Medical 
Research Councils (EMRC) provides important evi-
dence on funding and conducting effective, relevant, 
and world beating research (box 1).1 Summing up the 
white paper in Frankfurt last month, Professor Liselotte 
Højgaard, EMRC chair, quoted British physiologist 
Ernest Starling’s advice to the British Research Council 
in the 1920s, “get the best of men, give them the equip-
ment you can afford, and leave them alone.”
This white paper is one of several responses to last 
year’s green paper from the European Commission, 
which contained proposals on how to overcome the 
fragmentation of research activities, programmes, 
and policies across Europe.2 The EMRC’s response 
is a pragmatic and readable document that pulls 
together evidence on whether Europe is finding the 
best researchers and whether it is spending enough 
on research to give them the tools they need. It does 
not, however, advocate leaving these workers alone 
as Starling suggested. If research in basic science and 
clinical medicine is to be successfully translated into 
practice, all those responsible—peer reviewers, jour-
nal editors, authors of reviews and guidelines, policy 
makers, and researchers themselves—need adequate 
training, support, and evaluation. 
Many initiatives—such as the European roadmap 
for innovative research—are already in place across 
Europe for finding and training the best researchers in 
universities, laboratories, industry, and healthcare set-
tings.3 The EMRC endorses the best of these and puts 
them—along with research ethics,4 sharing of research 
data,5 and effective information technology and other 
essentials—into its toolbox for best practice (box 2). It 
also warns that unequal opportunities for researchers 
will hold Europe back. The white paper highlights the 
relative paucity of women among leaders of publicly 
funded research and in scientific decision making, and it 
stresses that women are less likely than men to succeed 
when applying for research grants of equal quality.
Is Europe providing the tools that its medical 
researchers need? With extra demands on health care 
Diagnosing what needs to be done is relatively easy; 
making it happen is much more difficult. An Organisation 
with a Memory emphasised how important it was for the 
NHS to learn from mistakes and to do this actively rather 
than passively. The analysis produced by the Healthcare 
Commission shows that this has yet to happen, so that 
inquiries and investigations in the future may find similar 
failings, unless leaders at all levels make a commitment to 
ensuring that quality and safety are taken seriously.
If this is to happen, the NHS needs to match its record 
of achievement as a “doing organisation” and become 
a “learning organisation.” Governments have rightly 
focused on priority areas—for example, cutting waiting 
times and improving areas of clinical priority such as 
cancer and heart disease—because of the legacy of poor 
performance in the NHS. Success in dealing with these 
priorities needs to be complemented by a focus on con-
tinuous quality improvement, in which clinical teams are 
supported to build on what works well and to learn from 
things that have gone wrong.
How to make this happen can be gleaned from a new 
study of high performing healthcare organisations in 
 different countries, which describes the journey taken 
by these organisations and the factors that have contrib-
uted to their success. As the study makes clear, achieving 
high levels of performance cannot be reduced to a cook-
book approach in which organisations implement lessons 
from the study of failure and success. A more nuanced 
approach is needed, starting from the position that each 
organisation has to find its own path of improvement 
appropriate to the context in which it operates and based 
on making changes on several fronts at the same time.
An area of common ground between this study and 
the report of the Healthcare Commission is the empha-
sis placed on leadership in bringing about change. Of 
particular relevance for the NHS is the commission’s 
view that continuity of leadership is important (one of 
the organisations it investigated had seven chief execu-
tives in 10 years). Strengthening leadership for quality 
improvement may be the key that will finally unlock 
the secret of learning from mistakes, provided that this 
is done in the clinical teams providing care as well as at 
board level.
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Box 1 | EMRC recommendations for strengthening 
medical research in Europe
• Implementation of best practice for funding and 
performing medical research—with distribution of funding 
based on excellence and evaluated by peer review
• Strengthened collaboration and coordination of medical 
research in Europe through the EMRC and its membership 
organisations, via the European Commission, the European 
Research Council, and the learned medical societies
• Revision of European Commission directives related to 
medical research
• Implementation of equal opportunities for all researchers
• A doubling of public funding of medical research in 
Europe within the next 10 years—to a minimum of 0.25% 
of gross domestic product
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that include an ageing population, emerging and rap-
idly spreading infectious diseases, and climate change, 
Europe needs to keep on its toes. But it is investing 
much less than the United States, which is facing the 
same challenges. In 2004, the US non-industrial sector 
spent twice as much as Europe on biomedical research 
(around 0.40% of gross domestic product compared 
with 0.17% in the EU15—the 15 countries in the Euro-
pean Union before the accession of 10 candidate coun-
tries on 1 May 2004—a difference that would have been 
greater if all EU countries were included) and almost 
three times as much when adjusted for the size of the 
two populations.1 The EMRC is calling for a doubling 
of public funding for medical research in Europe within 
the next 10 years and, at a minimum, spending the 
equivalent of 0.25% of gross domestic product.
Health research also has to compete within Europe 
for its slice of the science funding pie. The Seventh 
Framework Programme for Research and Technologi-
cal Development doubled overall funding for science 
research to more than €50bn (£37bn; $73bn) between 
2007 and 2013,6 but only €6.1bn of this will go to health 
research, with much more going to physics—participants 
at Frankfurt noted that particle accelerators are costly 
and physicists have a lot of influence in European 
 policy. Competing with other scientific funding is a 
challenge in the US too, and Elias Zerhouni, director 
of the US National Institutes of Health (NIH), has said, 
“if we don’t find ourselves at the table discussing the 
role of medical research, we’ll find ourselves on the 
menu” (Stefano Bertuzzi, science policy analyst at NIH, 
personal communication, Frankfurt, 2007).
Underfunding for medical research disadvantages 
Europe’s citizens, the white paper argues, because 
 medical research funding can yield up to a sixfold return 
on investment as a healthier population creates more 
wealth. But ways to evaluate the outputs and outcomes 
of research funding—including bibliometric analysis, 
 retrospective case studies, surveys, peer review, and eco-
nomic analysis—are still in their infancy, and the EMRC 
supports calls for common criteria and methods.7
Peer review largely determines which research is 
carried out and published, but it is a far from perfect 
tool. For instance, peer reviewers are biased towards 
American research,8 which might partly explain 
the 10% difference in citation rates for US and EU 
research. Moreover, we still know relatively little about 
the strengths and limitations of peer review, and the 
 evidence base is mainly about peer review of journal 
submissions rather than grant proposals. Worse still, 
peer review is given little support. Reviewers’ work-
load is constantly increasing, yet they receive no specific 
training, no protected time, and no academic recogni-
tion for this work. Indeed, the Frankfurt meeting heard 
that grant giving bodies are running short of good 
reviewers who are willing and able to appraise lengthy 
proposals, and it concluded that peer review of grant 
proposals needs better scrutiny and evaluation and 
much greater support.
Some good news for Europe emerged from the 
EMRC white paper—the research euro is getting a 
bigger bang than the research buck. Although the EU 
spends less on research than the US, it is producing only 
one medical research paper less than the US per 10 000 
inhabitants (3.9 papers v 4.9 in 2005).1 This says nothing 
about the quality of research, however, so the EMRC 
has also looked at citation rates. Between 1996 and 2003 
40% of the world’s citations to biomedical publications 
were for research done in the EU15 countries, com-
pared with 50% for work from the US. Given the big 
difference in funding, this reflects well on Europe. The 
challenge now is to keep on catching up.
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Box 2 | EMRC tool box: “best practice” for medical research in Europe
Primary goals
All three to be facilitated by interdisciplinary research and public-private partnerships
• Strong basic research
• Strong clinical research
• Strong translational research—sharing knowledge between research and practice
Tools to reach these goals: people
• Career track schemes with attractive possibilities for researchers taking advantage of 
cofunding strategy
• European Medical Scientific Training Programme for physicians and scientists scaling up 
existing successful initiatives
• The highest level of research ethics and no scientific misconduct
Tools to reach these goals: research infrastructure
• Investment in national and European research infrastructure—covering the whole 
range from laboratory equipment in basic science laboratories and research facilities 
in hospitals, to the largest pan-European infrastructures, as outlined in the European 
Strategy Forum on Research Infrastructure’s roadmap
• A call for proposals to directly support—on a highly competitive basis—a league of top 
performing biomedical research centres of excellence, integrated into regional clusters
•More support for personalised medicine based on the human genome and molecular 
analyses of tumour markers
• Intelligent and coordinated use of information technology
• Review of European Commission and national regulations—for example, on biobanks—to 
facilitate collaboration across countries
Tools to reach these goals: research funding
• Adequate research funding based on scientific excellence and high quality peer review
• Common criteria and methods for evaluating research outcomes
Tools to reach these goals: societal means
• Globalisation and collaboration—sharing of research and results
• Public engagement about medical research and its possible effects
•Preparedness for the future
